NAT10 exacerbates aortic valve calcification via PCSK9 mRNA ac4C acetylation
Abstract
N4-acetylcytidine (ac4C) is an epitranscriptomic regulator involved in diverse pathological processes. This study investigates the role of N-acetyltransferase 10 (NAT10), the primary enzyme responsible for ac4C deposition, in aortic valve calcification (AVC). NAT10 expression and global ac4C levels are upregulated in calcified aortic valves from human patients and murine models. Clinically, elevated NAT10 expression correlates with increased disease severity. Functionally, NAT10 promotes human valvular interstitial cells (hVICs) osteogenic differentiation. In high-cholesterol diet (HCD)-fed ApoE -/- mice, pharmacological NAT10 inhibition (via remodelin) or targeted degradation (via PROTAC NP1192) ameliorates AVC. Mechanistically, we identified the pro-calcific gene proprotein convertase subtilisin/kexin type 9 (PCSK9) as a downstream target of NAT10. NAT10 catalyzes the ac4C modification of PCSK9 mRNA, thereby enhancing its transcript stability. Collectively, our findings reveal a NAT10-ac4C-PCSK9 regulatory axis that amplifies AVC, establishing the NAT10/ac4C machinery as a promising therapeutic target for calcific aortic valve disease (CAVD).
Related
- Immobilzation‐Induced Muscle Atrophy Exacerbates Vascular Calcification and Abdominal Aortic Aneurysms Through Irisin Downregulation
- ASXL1-Mutant Clonal Hematopoiesis is Associated with Calcific Aortic Valve Disease and Promotes Valvular Calcification In Vitro
- Impact of diabetes mellitus on aortic valve calcification: a cross-sectional study of two large multicentre cohorts
- Posterior neo-annular reconstruction: An alternative approach to mitral valve replacement for caseous mitral annular calcification
- Mitral Transcatheter Edge-to-Edge Repair in a Challenging Anatomy With Deeply Implanted Self-Expanding Valve and Severe Mitral Annular Calcification: A Case Report
BibTeX
@article{liu2026nat10,
title = {{NAT10 exacerbates aortic valve calcification via PCSK9 mRNA ac4C acetylation}},
author = {Yinghuan Liu and Xianying Li and Tong Zhou and Jianhua Xie and Huirong Jiang and Baoping Zheng and Jiangtong Peng and Lifu Li and Dong Han and Yongjun Wang},
journal = {iScience},
year = {2026},
month = oct,
doi = {10.1016/j.isci.2026.117812},
url = {https://www.cell.com/iscience/fulltext/S2589-0042(26)03193-7},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - NAT10 exacerbates aortic valve calcification via PCSK9 mRNA ac4C acetylation
AU - Yinghuan Liu
AU - Xianying Li
AU - Tong Zhou
AU - Jianhua Xie
AU - Huirong Jiang
AU - Baoping Zheng
AU - Jiangtong Peng
AU - Lifu Li
AU - Dong Han
AU - Yongjun Wang
PY - 2026
DA - 2026/10/13
JO - iScience
DO - 10.1016/j.isci.2026.117812
UR - https://www.cell.com/iscience/fulltext/S2589-0042(26)03193-7
AB - N4-acetylcytidine (ac4C) is an epitranscriptomic regulator involved in diverse pathological processes. This study investigates the role of N-acetyltransferase 10 (NAT10), the primary enzyme responsible for ac4C deposition, in aortic valve calcification (AVC). NAT10 expression and global ac4C levels are upregulated in calcified aortic valves from human patients and murine models. Clinically, elevated NAT10 expression correlates with increased disease severity. Functionally, NAT10 promotes human valvular interstitial cells (hVICs) osteogenic differentiation. In high-cholesterol diet (HCD)-fed ApoE -/- mice, pharmacological NAT10 inhibition (via remodelin) or targeted degradation (via PROTAC NP1192) ameliorates AVC. Mechanistically, we identified the pro-calcific gene proprotein convertase subtilisin/kexin type 9 (PCSK9) as a downstream target of NAT10. NAT10 catalyzes the ac4C modification of PCSK9 mRNA, thereby enhancing its transcript stability. Collectively, our findings reveal a NAT10-ac4C-PCSK9 regulatory axis that amplifies AVC, establishing the NAT10/ac4C machinery as a promising therapeutic target for calcific aortic valve disease (CAVD).
SN - 2589-0042
ER -